Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
McKesson
Colorcon
Covington
Medtronic
Chinese Patent Office
Queensland Health
Fish and Richardson
Johnson and Johnson
McKinsey

Generated: January 16, 2018

DrugPatentWatch Database Preview

ADENOSCAN Drug Profile

« Back to Dashboard

Which patents cover Adenoscan, and when can generic versions of Adenoscan launch?

Adenoscan is a drug marketed by Astellas and is included in one NDA.

The generic ingredient in ADENOSCAN is adenosine. There are twenty-six drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the adenosine profile page.

US Patents and Regulatory Information for ADENOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-001 May 18, 1995 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-002 May 18, 1995 DISCN Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for ADENOSCAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-001 May 18, 1995 ➤ Subscribe ➤ Subscribe
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-001 May 18, 1995 ➤ Subscribe ➤ Subscribe
Astellas ADENOSCAN adenosine SOLUTION;IV (INFUSION) 020059-002 May 18, 1995 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ADENOSCAN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 4/16/2005
➤ Subscribe Injection 3 mg/mL, 20 mL and 30 mL vials ➤ Subscribe 4/18/2005

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Chubb
Medtronic
Novartis
Harvard Business School
QuintilesIMS
Citi
Argus Health
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot